Newswise — The field of gene therapy promises to dramatically transform the treatment of disease, as well as fundamentally change the delivery of healthcare in the twenty-first century. With an acceleration of advances taking place in the field, a new book provides a comprehensive review of the field of gene-based therapeutics in an expanded third edition textbook that concentrates on advances in areas that were in their infancy when the last edition was published in 2002.
The new book, Gene Therapy of Cancer Translational Approaches from Preclinical Studies to Clinical Implementation 3 (Elsevier Limited, Oxford, United Kingdom) http://www.elsevier.com/books/gene-therapy-of-cancer/lattime/978-0-12-394295-1 is co-edited by internationally recognized investigators Stanton L. Gerson, MD, Case Western Reserve University (CWRU) School of Medicine, and Edmund C. Lattime, PhD, Rutgers Cancer Institute of New Jersey.
The book places a new focus on studies in the expanded efforts in oncolytic viruses and genetic fusion vaccines, taking advantage of recent clinical advancements. The 3rd edition concentrates on advances in non-viral vector development, including the use of inhibitory RNA. Further emphasis has been added on the defined field of drug resistance gene therapy, as well as on the use of imaging factors in gene therapy approaches. New chapters cover insider perspectives on regulatory review and approval from the National Cancer Institute and the Food and Drug Administration.
“Gene therapy is revolutionizing the world of medicine,” said Stanton Gerson, MD, director of the National Center for Regenerative Medicine and the Case Comprehensive Cancer Center, at CWRU, and director of the Seidman Cancer Center at UH Case Medical Center and Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology at CWRU. “We are at the water shed point in the use of gene therapy for cancer, as in many other fields. We expect that this will change the practice of cancer treatment both in areas of vaccine development, and new treatments for advanced disease,” said Gerson.
“Because of a plethora of advances since the textbook was last published, Dr. Lattime and I undertook a complete revamp of the content, authors and scientific focal areas to emphasize in this a new, revised edition of Gene Therapy. This textbook serves as an essential reference for scientists, researchers, practitioners and students that are embracing the latest advances in gene therapy technology and clinical application,” said Gerson.
Publication of Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation 3rd edition is scheduled for international release and distribution the third week of September, 2013.
Dr. Stanton Gerson has earned multiple National Institutes of Health (NIH) grants and published more than 220 journal articles, 260 abstracts and 29 book chapters. Gerson is also co-editor of the textbook Clinical Hematology, published in 2005. His research has led to 16 patents in gene therapy and cancer drug development, which have been licensed to three companies.
Edmund C. Lattime, PhD, is the deputy director at Rutgers Cancer Center Institute of New Jersey, as well as the Associate Director for Education and Training. He is also a Professor of Surgery, and Professor of Biochemistry and Molecular Genetics, at the Rutgers Robert Wood Johnson Medical School. ###About Case Western Reserve University School of Medicine Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation’s top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School’s innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.
Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report’s “Guide to Graduate Education.”
The School of Medicine’s primary affiliate is University Hospitals Case Medical Center and is additionally affiliated with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. http://casemed.case.edu
About Case Comprehensive Cancer Center Case Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center located at Case Western Reserve University. The center, now in its 25th year of funding, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve, University Hospitals (UH) Case Medical Center and the Cleveland Clinic. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer.